ARQIS has advised the selling shareholders of the biotech start-up IMD Natural Solutions on the deal
Financial details of the transaction were not disclosed.
IMD Natural Solutions develops novel active ingredients from sustainable natural resources for the food, beverage and consumer goods industries. The focus is on the research and development of natural substances with antimicrobial effects.
For LANXESS the acquisition is an important step towards becoming fit for the future in the growing market for natural active ingredients. LANXESS is a leading specialty chemicals company with sales of EUR 9.7 billion in 2017 and about 19,200 employees in 25 countries. The core business of LANXESS is the development, manufacturing and marketing of chemical intermediates, additives, specialty chemicals and plastics. Through ARLANXEO, the joint venture with Saudi Aramco, LANXESS is also a leading supplier of synthetic rubber.
ARQIS Rechtsanwälte advised IMD Natural Solutions with a team including Mirjam Boche (Picture; Corporate/M&A), Marcus Nothhelfer (IP; Munich);Franziska Korn (Corporate/M&A) and Philipp Maier (IP; Munich).
Law Firms: Arqis;
Clients: IMD Natural Solutions GmbH;